Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Posted by Brian Himes on Aug 5th, 2026

Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12, FiscalAI reports. Editas Medicine had a negative net margin of 281.59% and a negative return on equity of 677.39%. The business had revenue of $11.89 million during the quarter, compared to the consensus estimate of $2.85 million.

Editas Medicine Stock Performance

Editas Medicine stock traded down $0.01 during midday trading on Wednesday, hitting $2.75. 1,935,184 shares of the company’s stock were exchanged, compared to its average volume of 2,030,220. Editas Medicine has a 12-month low of $1.66 and a 12-month high of $4.54. The stock has a market cap of $269.73 million, a price-to-earnings ratio of -2.24 and a beta of 2.14. The firm’s 50 day simple moving average is $2.94 and its 200 day simple moving average is $2.63.

Analyst Ratings Changes

Several equities research analysts recently commented on EDIT shares. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research note on Wednesday, May 27th. Wall Street Zen downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. Chardan Capital lifted their target price on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.40.

Read Our Latest Analysis on Editas Medicine

Insider Activity at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the completion of the sale, the chief executive officer directly owned 248,313 shares of the company’s stock, valued at approximately $670,445.10. This represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,503 shares of company stock valued at $57,910 over the last three months. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in Editas Medicine by 138.0% during the 4th quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock valued at $6,232,000 after acquiring an additional 1,762,378 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Editas Medicine by 122.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Editas Medicine by 761.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company’s stock valued at $2,776,000 after purchasing an additional 707,181 shares during the period. Two Sigma Investments LP raised its stake in shares of Editas Medicine by 63.3% during the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock worth $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Editas Medicine by 288.5% during the first quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock worth $869,000 after purchasing an additional 558,567 shares during the period. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.